Losartan Potassium
Product Images NDC 67296-2057

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 67296-2057). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

25 mg,90 Tablets/bottle (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 06)

Losartan Potassium Tablets USP 25 mg label showing a 90-tablet bottle by Solco Healthcare US, distributed by RedPharm Drug. The label includes storage instructions, manufacturer details in China, and a note for pharmacists to dispense with an information leaflet. The NDC shown is 43547-360-09.*

FDA Label Image

50 mg 30 Tablets (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 07)

Losartan Potassium Tablets, USP 50 mg label showing 30 scored tablets. The label includes storage instructions, manufacturer Zhejiang Huahai Pharmaceutical Co., Ltd., and distributor Solco Healthcare US, LLC. It features a blue and purple design with a barcode and dispensing information.*

FDA Label Image

100 mg 30 Tablets (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 08)

Label for Losartan Potassium Tablets, USP 100 mg showing a 30 tablet count. The label includes storage instructions, manufacturer Zhejiang Huahai Pharmaceutical Co., Ltd., and distributor Solco Healthcare US, LLC. It features a blue and gold design with a note for pharmacists to dispense with patient information leaflet.*

FDA Label Image

Chemical Structure (Spl Image1 Structure1)

Chemical structure of Losartan Potassium, showing its molecular components including a chlorinated pyrimidine ring, a biphenyl group, and a potassium ion (K+).*

FDA Label Image

Figure 1 (Spl Image2 Figure1)

A line graph comparing the percentage of patients with the primary endpoint over study months for Atenolol and Losartan Potassium. The graph shows Atenolol with a dotted line and Losartan Potassium with a solid line, indicating risk reduction over approximately 66 months with annotated adjusted risk reduction at 13%, p=0.021.*

FDA Label Image

Figure 2 (Spl Image3 Figure2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over 66 months for Atenolol and Losartan Potassium. The graph shows risk reduction data with adjusted risk reduction of 25%, p=0.001, highlighting differences in stroke incidence between the two treatments over time.*

FDA Label Image

Figure 3 (Spl Image4 Figure3)

A forest plot chart titled 'Primary Endpoint Events within Demographic Subgroups' comparing event rates and hazard ratios of Losartan Potassium versus Atenolol. The chart presents subgroups by age, gender, race, ISH, diabetes, and cardiovascular disease history. It displays primary composite and stroke (fatal/non-fatal) event rates, with hazard ratio estimates and confidence intervals indicating relative favorability.*

FDA Label Image

Figure 4 (Spl Image5 Figure4)

A line graph showing the percentage of patients with an event over 48 months, comparing Losartan Potassium (solid line) versus Placebo (dotted line). The graph includes a note of 16.1% risk reduction with a p-value of 0.022.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.